A Pharmaceutical Company's View on Supply-Chain Security: A Perspective from Pfizer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Pharmaceutical Company's View on Supply-Chain Security: A Perspective from Pfizer
The author offers perspectives on ways in which pharmaceutical companies and other stakeholders in the supply chain can confront the threat of counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration.


Pharmaceutical Technology
Volume 35, Issue 9

A dangerous melamine substitution in nutritional products in China, the $75-million heist of drugs from Eli Lilly's Connecticut warehouse, and 149 deaths in the US from contaminated heparin are all examples of headline-making news stories of pharmaceutical supply-chain attacks. These types of threats are occurring with greater frequency, and concern for patient safety is escalating. Counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration are creating greater challenges for Pfizer and other global pharmaceutical companies while putting patient safety at risk.

The World Health Organization (WHO) estimates that 10% of all pharmaceuticals in the global supply chain are counterfeit, and that level may reach 70% in some developing countries (1). Although it is impossible to accurately quantify the extent of the global problem, the impact of counterfeiting has been estimated to be as high as $200 billion per year (2). Other supplychain security problems also are on the rise. From 2007 to 2009, for example, the rate of pharmaceutical cargo theft in the US jumped 350% (3).

Contributing factors

Several business trends are contributing to the problem. Cost and pricing pressures, generic-drug competition, and challenges with R&D productivity, coupled with the loss of exclusivity of key products—all are pushing pharmaceutical companies toward more complex supply chains, increased levels of contract manufacturing, and more licensing agreements. These issues, along with companies' efforts to expand into new and emerging markets, are providing ample opportunity for criminals to illegally enter the supply chain.

Partnerships

We all realize that we operate in a global marketplace. The pharmaceutical industry's raw materials may originate in one part of the world while products are manufactured in another. Packaging can occur in many markets, and products are transported and sold globally. Supply-chain security is an international issue and a global health imperative.

To successfully address the problem, pharmaceutical companies, regulators, suppliers, law enforcement, and other supply-chain partners must work closely and cooperatively together. Collaboration already is occurring through organizations such as Rx–360, World Health Organization, the Pharmaceutical Security Institute, the Partnership for Safe Medicines, and Interpol to name a few.

The pharmaceutical industry, consumers, and the public at large should realize that we are all in this together. Effective global solutions are required to shore up the entire supply-chain security system because criminals will always attack the weakest links to steal, divert, counterfeit, or adulterate drug products.

The main players in the supply chain—pharmaceutical companies and their external partners, trade groups, law enforcement, government agencies, and industry consortiums—can influence change. Whether by working together or in part (i.e., as a group proposing a strategy, by influencing another partner in the chain, by supporting an initiative, or by implementing a specific requirement), we can, for example, increase global penalties for supply-chain crimes, increase public awareness of supply-chain risks, share best practices, and work to develop harmonized global supply-chain solutions. We must embrace opportunities for the industry and its stakeholders to work together to keep the pharmaceutical supply chain safe for millions of patients who depend upon the products it provides to improve their lives. They expect safe and effective medicines, and it is the industry's responsibility to deliver them.

Holistic approach to supply-chain security

External partnerships and cooperation are vital to keep the global supply of medicines safe, but pharmaceutical companies also can do a great deal to maximize supply-chain security at the organizational level within their companies. The industry can start by taking a holistic approach to supply-chain security from the procurement of raw materials through product delivery. Risk-management principles and integrated layers of protection are important at each juncture of the supply-chain continuum. Pharmaceutical companies need to understand and integrate the myriad internal organizations and activities that touch their supply chains and collaborate to reach effective solutions.

The areas that make up the supply chain—including raw-materials procurement, manufacturing (internal manufacturing and through external suppliers), transportation, warehousing, quality, distribution, and marketplace monitoring—must be aligned and work together for maximum effectiveness.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here